Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528372 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,067
- Enrollment target
NCT00528372 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,067 participants.
The verdict
NCT00528372, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,067 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this treatment will also be studied.
Interventions
- DRUG Metformin
- DRUG Dapagliflozin
- DRUG Dapagliflozin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,067 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528372
The ClinicalTrials.gov registry entry for NCT00528372 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00528372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528372 about?
NCT00528372 is a clinical study titled "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise". The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. Th...
What is the current status of trial NCT00528372?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,067 participants. The study started on 2007-09. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00528372?
The interventions under investigation include: Metformin (DRUG), Dapagliflozin (DRUG), Dapagliflozin placebo (DRUG).
Who is sponsoring clinical trial NCT00528372?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.